HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

J Erfan Selected Research

IMO-2055

12/2014Phase 2, open-label, 1:1 randomized controlled trial exploring the efficacy of EMD 1201081 in combination with cetuximab in second-line cetuximab-naïve patients with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN).

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


J Erfan Research Topics

Disease

1Squamous Cell Carcinoma of Head and Neck
12/2014
1Dyspnea (Shortness of Breath)
12/2014
1Hypokalemia
12/2014
1Respiratory Insufficiency (Respiratory Failure)
12/2014
1Disease Progression
12/2014

Drug/Important Bio-Agent (IBA)

1IMO-2055IBA
12/2014
1Cetuximab (Erbitux)FDA Link
12/2014